Such experiments are necessary to explore whether it may be possible to alleviate some of the more severe symptoms of ERCC1-XPF or XPG deficiency in human patients as well, possibly by therapeutically targeting XPA or TTDA. The gene discussed is XPA; the disease is hyperinsulinemic hypoglycemia, familial, 4.